›Supplement with IV analgesia if inadequate
›Procedural sedation
›Ketamine IV 1-2 mg/kg for dissociative sedation
›Onset 60-90 seconds
›Duration 10-20 minutes
›Propofol IV 1-2 mg/kg induction dose
›Airway management equipment at bedside
›Fasting status assessment
›Midazolam plus fentanyl
›Midazolam 0.05-0.1 mg/kg IV
›Fentanyl 1-2 mcg/kg IV
›Ultrasound-guided nerve block
›Distal median nerve block at wrist level
›3-5 mL 1% lidocaine under real-time ultrasound guidance
›Targets median nerve in carpal tunnel
›Forearm-level brachial plexus block
›Consider for complex reductions
›Anesthesia or trained ED provider
Closed reduction technique
›Reduction maneuver steps
›Longitudinal traction applied to fingers
›Finger trap traction or manual traction
›5-10 minutes of traction to disimpact fragments
›Distal fragment manipulation
›Correct dorsal angulation
›Restore volar tilt and radial length
›Ulnar deviation to correct radial shortening
›Restore radial inclination
›Maintain reduction while splint applied
›Acceptable post-reduction alignment
›Radial shortening < 3 mm
›Compared to contralateral wrist
›Dorsal tilt < 10 degrees (volar tilt preferred)
›Aim for restoration of neutral or volar tilt
›No significant intra-articular step-off
›Step-off < 2 mm acceptable
›Post-reduction films mandatory before splint finalized
›Splinting technique
›Sugar-tong splint for displaced fractures post-reduction
›Prevents forearm rotation
›Wrist in neutral to slight volar flexion and ulnar deviation
›Volar short-arm splint for non-displaced stable fractures
›Wrist in neutral position
›Thumb spica extension if scaphoid injury suspected
›Splint to cast transition
›Short-arm cast at 1-2 week follow-up
›Once swelling subsided
›Confirm maintained alignment before cast application
›Immobilization duration
›Non-displaced fractures: 3-6 weeks total
›Recent evidence supports 3 weeks for stable non-displaced fractures
›Displaced or reduced fractures: 6 weeks typical
›Indications for operative fixation
›Persistent instability after closed reduction
›Radial shortening > 3 mm
›Dorsal tilt > 10 degrees
›Articular step-off > 2 mm
›Open fracture
›Cefazolin 2 g IV initiated within 1 hour of presentation
›Washout and debridement in OR
›Acute vascular injury or compartment syndrome
›Fasciotomy and fracture stabilization combined
›Surgical fixation options
›Volar locking plate (most common)
›No difference in functional outcomes between fixation techniques at 3 months
›Preferred for most unstable patterns
›Percutaneous K-wire fixation
›Cochrane review: similar functional outcomes to plate at 1 year
›Lower cost; risk of pin tract infection and stiffness
›External fixation
›Complex comminution or open fractures
›Adjunct to internal fixation in some patterns
›Geriatric surgical considerations
›Age >= 65 years: no functional benefit of surgery over conservative management
›CROSSFIRE trial: equivalent patient-reported outcomes
›Conservative management preferred in most geriatric patients
›Exceptions may include bilateral fractures or specific functional demands
›Individualized shared decision-making
›Comorbidity and anesthetic risk assessment
Post-fracture bone health
›Osteoporosis pharmacotherapy indications
›Bisphosphonate therapy for high-risk patients
›Alendronate 70 mg PO weekly (ACP/AACE guideline)
›Risedronate 35 mg PO weekly as alternative
›Zoledronic acid 5 mg IV annual infusion
›For patients unable to tolerate oral bisphosphonates
›ACEP and ACP support initiation after fragility fracture
›Calcium and vitamin D supplementation
›Calcium 1000-1200 mg/day in divided doses
›Vitamin D 600-800 IU/day (higher doses for deficiency)
›Denosumab 60 mg SC every 6 months
›For severe osteoporosis or bisphosphonate intolerance
›Do not discontinue without bridging therapy (rebound fracture risk)